Stock Track | COMPASS Pathways Soars 9.20% in Pre-market After Trump's Executive Order Supports Psychedelic Treatments

Stock Track04-21 16:08

COMPASS Pathways plc (CMPS) saw its stock price surge 9.20% in pre-market trading, continuing a significant rally for the psychedelic medicine developer.

The sharp increase follows an executive order signed by President Donald Trump aimed at opening up access to psychedelic treatments for mental illnesses. The order includes $50 million in research funding and regulatory changes to expedite the approval process for these therapies. Specifically, it allows companies with breakthrough-therapy designations to receive vouchers that speed up regulatory review, which applies to COMPASS Pathways' psilocybin treatment for treatment-resistant depression.

Analysts view the executive order as substantially reducing regulatory risk for psychedelic therapies, with RBC Capital Markets noting it represents "a substantial step towards diminishing regulatory risk in this emerging class of therapies." The order also enables patient access through the Right to Try Act and calls for rapid rescheduling of Schedule 1 drugs that complete Phase 3 trials for mental illness treatments.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1155367656?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-21 16:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155367656","market":"sg","top_or_hot":-1,"title":"Stock Track | COMPASS Pathways Soars 9.20% in Pre-market After Trump's Executive Order Supports Psychedelic Treatments","media":"Stock Track","content":"<p>COMPASS Pathways plc (CMPS) saw its stock price surge 9.20% in pre-market trading, continuing a significant rally for the psychedelic medicine developer.</p><p>The sharp increase follows an executive order signed by President Donald Trump aimed at opening up access to psychedelic treatments for mental illnesses. The order includes $50 million in research funding and regulatory changes to expedite the approval process for these therapies. Specifically, it allows companies with breakthrough-therapy designations to receive vouchers that speed up regulatory review, which applies to COMPASS Pathways' psilocybin treatment for treatment-resistant depression.</p><p>Analysts view the executive order as substantially reducing regulatory risk for psychedelic therapies, with RBC Capital Markets noting it represents \"a substantial step towards diminishing regulatory risk in this emerging class of therapies.\" The order also enables patient access through the Right to Try Act and calls for rapid rescheduling of Schedule 1 drugs that complete Phase 3 trials for mental illness treatments.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | COMPASS Pathways Soars 9.20% in Pre-market After Trump's Executive Order Supports Psychedelic Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | COMPASS Pathways Soars 9.20% in Pre-market After Trump's Executive Order Supports Psychedelic Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-21 16:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>COMPASS Pathways plc (CMPS) saw its stock price surge 9.20% in pre-market trading, continuing a significant rally for the psychedelic medicine developer.</p><p>The sharp increase follows an executive order signed by President Donald Trump aimed at opening up access to psychedelic treatments for mental illnesses. The order includes $50 million in research funding and regulatory changes to expedite the approval process for these therapies. Specifically, it allows companies with breakthrough-therapy designations to receive vouchers that speed up regulatory review, which applies to COMPASS Pathways' psilocybin treatment for treatment-resistant depression.</p><p>Analysts view the executive order as substantially reducing regulatory risk for psychedelic therapies, with RBC Capital Markets noting it represents \"a substantial step towards diminishing regulatory risk in this emerging class of therapies.\" The order also enables patient access through the Right to Try Act and calls for rapid rescheduling of Schedule 1 drugs that complete Phase 3 trials for mental illness treatments.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMPS","symbol_name":"COMPASS Pathways plc","start_time":0,"source_url":"","article_id":"1155367656","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155367656","pubTimestamp":1776758919,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"COMPASS Pathways plc (CMPS) saw its stock price surge 9.20% in pre-market trading, continuing a significant rally for the psychedelic medicine developer.The sharp increase follows an executive order...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CMPS":"COMPASS Pathways plc"},"translate_title":"个股追踪|特朗普行政令支持迷幻疗法后COMPASS Pathways盘前大涨9.20%","themeId":"b19553a137a2d518dfc18efdd547e678","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMPS":1},"content_text":"COMPASS Pathways plc (CMPS) saw its stock price surge 9.20% in pre-market trading, continuing a significant rally for the psychedelic medicine developer.The sharp increase follows an executive order signed by President Donald Trump aimed at opening up access to psychedelic treatments for mental illnesses. The order includes $50 million in research funding and regulatory changes to expedite the approval process for these therapies. Specifically, it allows companies with breakthrough-therapy designations to receive vouchers that speed up regulatory review, which applies to COMPASS Pathways' psilocybin treatment for treatment-resistant depression.Analysts view the executive order as substantially reducing regulatory risk for psychedelic therapies, with RBC Capital Markets noting it represents \"a substantial step towards diminishing regulatory risk in this emerging class of therapies.\" The order also enables patient access through the Right to Try Act and calls for rapid rescheduling of Schedule 1 drugs that complete Phase 3 trials for mental illness treatments.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1155367656","isCrawlerRequest":true}